These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 38540351)

  • 1. Drug Repurposing and Lysosomal Storage Disorders: A Trick to Treat.
    Hay Mele B; Rossetti F; Cubellis MV; Monticelli M; Andreotti G
    Genes (Basel); 2024 Feb; 15(3):. PubMed ID: 38540351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enzyme enhancement therapeutics for lysosomal storage diseases: Current status and perspective.
    Thomas R; Kermode AR
    Mol Genet Metab; 2019 Feb; 126(2):83-97. PubMed ID: 30528228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitochondrial Dysfunction and Neurodegeneration in Lysosomal Storage Disorders.
    Plotegher N; Duchen MR
    Trends Mol Med; 2017 Feb; 23(2):116-134. PubMed ID: 28111024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From rare to common and back again: 60years of lysosomal dysfunction.
    Coutinho MF; Alves S
    Mol Genet Metab; 2016 Feb; 117(2):53-65. PubMed ID: 26422115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emptying the stores: lysosomal diseases and therapeutic strategies.
    Platt FM
    Nat Rev Drug Discov; 2018 Feb; 17(2):133-150. PubMed ID: 29147032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exosome- and extracellular vesicle-based approaches for the treatment of lysosomal storage disorders.
    Lu B; Ku J; Flojo R; Olson C; Bengford D; Marriott G
    Adv Drug Deliv Rev; 2022 Sep; 188():114465. PubMed ID: 35878794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving therapies in neuronopathic LSDs: opportunities and challenges.
    Rajan DS; Escolar ML
    Metab Brain Dis; 2022 Oct; 37(7):2245-2256. PubMed ID: 35442005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delineating the Neuropathology of Lysosomal Storage Diseases Using Patient-Derived Induced Pluripotent Stem Cells.
    Sabitha KR; Chandran D; Shetty AK; Upadhya D
    Stem Cells Dev; 2022 May; 31(9-10):221-238. PubMed ID: 35316126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA orphan drug designations for lysosomal storage disorders - a cross-sectional analysis.
    Garbade SF; Zielonka M; Mechler K; Kölker S; Hoffmann GF; Staufner C; Mengel E; Ries M
    PLoS One; 2020; 15(4):e0230898. PubMed ID: 32267884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stem Cell Applications in Lysosomal Storage Disorders: Progress and Ongoing Challenges.
    Köse S; Aerts-Kaya F; Uçkan Çetinkaya D; Korkusuz P
    Adv Exp Med Biol; 2021; 1347():135-162. PubMed ID: 33977438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysosomal storage diseases: current therapies and future alternatives.
    Leal AF; Espejo-Mojica AJ; Sánchez OF; Ramírez CM; Reyes LH; Cruz JC; Alméciga-Díaz CJ
    J Mol Med (Berl); 2020 Jul; 98(7):931-946. PubMed ID: 32529345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dysregulation of autophagy as a common mechanism in lysosomal storage diseases.
    Seranova E; Connolly KJ; Zatyka M; Rosenstock TR; Barrett T; Tuxworth RI; Sarkar S
    Essays Biochem; 2017 Dec; 61(6):733-749. PubMed ID: 29233882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lysosomal storage disorders - challenges, concepts and avenues for therapy: beyond rare diseases.
    Marques ARA; Saftig P
    J Cell Sci; 2019 Jan; 132(2):. PubMed ID: 30651381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzyme Replacement Therapy: A Review and Its Role in Treating Lysosomal Storage Diseases.
    Li M
    Pediatr Ann; 2018 May; 47(5):e191-e197. PubMed ID: 29750286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysosomal storage diseases.
    Platt FM; d'Azzo A; Davidson BL; Neufeld EF; Tifft CJ
    Nat Rev Dis Primers; 2018 Oct; 4(1):27. PubMed ID: 30275469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cell biology of disease: lysosomal storage disorders: the cellular impact of lysosomal dysfunction.
    Platt FM; Boland B; van der Spoel AC
    J Cell Biol; 2012 Nov; 199(5):723-34. PubMed ID: 23185029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AISF update on the diagnosis and management of adult-onset lysosomal storage diseases with hepatic involvement.
    Nascimbeni F; Dionisi Vici C; Vespasiani Gentilucci U; Angelico F; Nobili V; Petta S; Valenti L;
    Dig Liver Dis; 2020 Apr; 52(4):359-367. PubMed ID: 31902560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SNX8 enables lysosome reformation and reverses lysosomal storage disorder.
    Li X; Xiang C; Zhu S; Guo J; Liu C; Wang A; Cao J; Lu Y; Neculai D; Xu P; Feng XH
    Nat Commun; 2024 Mar; 15(1):2553. PubMed ID: 38519472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From bedside to cell biology: a century of history on lysosomal dysfunction.
    Coutinho MF; Matos L; Alves S
    Gene; 2015 Jan; 555(1):50-8. PubMed ID: 25275857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymer-based drug delivery systems under investigation for enzyme replacement and other therapies of lysosomal storage disorders.
    Placci M; Giannotti MI; Muro S
    Adv Drug Deliv Rev; 2023 Jun; 197():114683. PubMed ID: 36657645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.